Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI takes on prostate cancer: could a computer spot hidden spread?

NCT ID NCT06253065

Diagnosis Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an artificial intelligence (AI) model designed to detect whether prostate cancer has spread to nearby lymph nodes. Researchers used digital images of lymph node tissue from 225 prostate cancer patients and compared the AI's accuracy to standard pathology reports. The goal was to see if the AI could help doctors diagnose lymph node metastasis more reliably in real-world settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Artificial intelligence (AI) diagnostic model
What this could lead to
If successful, this AI model could help pathologists diagnose lymph node spread more accurately and efficiently, potentially improving treatment decisions for prostate cancer patients.
What could go wrong
This is a completed diagnostic study with 225 participants, so results are available but may not generalize to all hospitals or patient groups. The AI model's performance depends on slide quality and may not outperform human pathologists in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

225 people

The number who actually took part.

Started

Jan 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with prostate cancer, (will) undergo radical prostatectomy and pelvic lymph node dissection between Jan, 2024 and Dec 2025 in Sun Yat-sen Memorial Hospital of Sun Yat-sen University are planned to be enrolled in this prospective diagnostic test. Histopathological slides of resected pelvic lymph nodes of enrolled patients will be collected and digitised as whole-slide images (WSIs) for prospective validation of the AI model.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients with prostate cancer, undergoing radical prostatectomy and pelvic lymph node dissection. * Patients with complete clinical and pathological information. Exclusion Criteria: * Patients with other tumors that metastasized to pelvic lymph nodes. * The patient refused to participate in this diagnostic test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphatic metastasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lymphatic Metastasis metastatic malignant neoplasm in the lymph nodes prostate cancer prostate neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphatic metastasis Prostatic neoplasms

Contacts and locations

Locations

  • Sun Yat-sen Memorial Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, 510120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.